Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
National emergency
Netflix
SpaceX
Venezuela
Mark Consuelos
Jussie Smollett
Michael Cohen
Biggest bee
Dog church
TXT
JAXA
Health News
Jan. 19, 2019 / 4:41 PM

FDA: Irbesartan lots recalled over likely carcinogen

By
Sommer Brokaw
Blood pressure manometer and medication. Photo by ronstik/Shutterstock

Jan. 19 (UPI) -- A drug company has recalled more irbesartan blood pressure medication after discovering a potential human carcinogen.

Prinston Pharmaceutical, doing business as Solco Healthcare, has voluntarily recalled of eight more lots of irbesartan blood pressure medication after detecting trace amounts of impurity in an active pharmaceutical ingredient, the Food and Drug Administration announced Friday.

The ingredient in question contains N-nitrosodiethylamine (NDEA), "a substance that occurs nationally in certain foods, drinking water, air pollution, and industrial processes" and has been classified by the International Agency for Research on Cancer as a probable human carcinogen.

NDEA was manufactured by a factory in China called Zhejiang Huahai Pharmaceuticals, which has been linked to several recalls of blood pressure drugs dating back to July.

RELATED Study: Soft drinks, exercise, hot temps increase risk for kidney disease

Lots of other blood pressure and heart medications such as valsartan, losartan, amlopidine and hydrochlorothiazide have also been recalled since July.

The FDA issued an import alert in September to block products made at the China plant from entering America and issued a warning letter in November about challenges including impurity control.

Hetero Labs, another factory in India, has also been linked to multiple recalls.

RELATED Heart healthy diet reduces diabetes risk, study says

Prinston will only be recalling lots of irbesartan-containing products that contain NDEA above the acceptable intake levels released by the FDA.

"Patients who are on Irbesartan should continue taking their medication, until their pharmacist provides a replacement, or their doctor prescribes a different medication that treats the same condition as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment," the FDA statement said.

RELATED Black teens see twice the junk food ads as white teens, study says
  • Topics
  • Food and Drug Administration
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Report: The number of cancer survivors grows as oncologists dwindle
Alzheimer's breakthrough may come from bone marrow experiment with mice
U.S. women have lower blood pressure, more obesity than men, study says
Teens view anxiety, depression as biggest problems in lives, study says
Kratom poison control calls up more than 50-fold from 2011 to 2017

Photo Gallery

 
Palestinians celebrate Valentine's Day

Latest News

House Democrats to raise bill Friday to stop Trump's border wall 'emergency'
Google Doodle honors 'Crocodile Hunter' Steve Irwin
Chris Pratt, Ethan Hawke face off in trailer for western 'The Kid'
2 sons of 'El Chapo' indicted by U.S. on drug conspiracy charges
Police seek suspects for Bangladesh fire
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy